Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.
Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially wth abiraterone acetate (ZYTIGA) plus prednisone.
The study was one of several related to sipuleucel-T presented at the European Cancer Congress in Amsterdam, the Netherlands.
In the phase II study, patients with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer were co-administered sipuleucel-T (three infusions at weeks 0, 2, and 4) with concurrent or sequential abiraterone plus placebo (abiraterone, 1,000 mg daily, plus placebo, 5 mg twice daily for ≤26 weeks). Patients were randomized 1:1 to abiraterone plus placebo starting either 1 day (concurrent) or 10 weeks (sequential) after the first sipuleucel-T infusion. The study’s primary endpoint was antigen-presenting cell (APC) activation; additional endpoints included APC and total nucleated cell (TNC) counts (sipuleucel-T product potency measures), immune responses, adverse events, and efficacy.
The authors, led by Eric J. Small, MD, of the University of California, San Francisco, reported that median cumulative APC activation and APC and TNC counts did not differ between the two arms (p>.05). APC activation increased with the second and third sipuleucel-T infusions in both arms, indicating a prime-boost effect. No differences were seen between arms in the robust peripheral antibody and T cell responses observed (p>.05).
Overall adverse event incidence was 96.9% in the concurrent arm and 87.5% in the sequential arm. However, most adverse events were infusion related, occurring within 1 day of infusion (53.1% and 65.6% of total population, respectively).
"These preliminary data are encouraging, and suggest that combining sipuleucel-T and abiraterone acetate plus prednisone is possible. It is not known if the potential for an immunostimulatory effect from low testosterone levels achieved with abiraterone may be offset by the potentially immunosuppressive effects of prednisone," Dr. Small said. "This study demonstrated that the co-administration of sipuleucel-T with abiraterone acetate and prednisone was generally well tolerated, and did not affect the product characteristics of sipuleucel-T nor its capacity to show an immune response."
Dr. Small is an advisory board member for and conducts corporate-sponsored research for Dendreon. Several of his co-authors are advisory board members of; have ownership in; are employees of; and/or have other substantive relationships with Dendreon.
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.